Evidence map›Paper›PMID 22445322›Full record

ArticlePlasmid2012

Low copy expression vectors for use in Yersinia sp. and related organisms.

Markus W Obrist, Virginia L Miller

Open access · greenAbstract read
In one paragraph

Article in Plasmid, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. The acquisition ofmBio · 2026
    Article
  2. The acquisition ofbioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. CsrA-Mediated Translational Activation of theJournal of bacteriology · 2023
    Article
  5. Article
  6. Status quo of tet regulation in bacteria.Microbial biotechnology · 2022
    Review
  7. Article
  8. ACS infectious diseases · 2021
    Article
  9. Article
  10. Article
  11. Temperature Control ofJournal of bacteriology · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Markus W ObristDepartment of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC 27599, United States.
Virginia L Miller
University of North Carolina at Chapel Hill · US

Funding

Transcriptional Activation by Small RNA: Mechanism and Design RulesR01GM090293 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, HAO, LI, LONG-CHENG · 2009 to 2013
$2.3M
YsrRS regulon of Y. enterocoliticaR01AI063299 · NIAID · WASHINGTON UNIVERSITY · PI MILLER, VIRGINIA L · 2005 to 2009
$1.1M
Small RNA targeted gene activation for the treatment of prostate cancerR21CA131774 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, LONG-CHENG · 2008 to 2009
$382k
NCI NIH HHS R21 CA131774NIAID NIH HHS AI063299NIAID NIH HHS R01 AI063299NIGMS NIH HHS R01 GM090293
6 · The paper itself

Abstract

In Yersinia, the most commonly used expression vectors for genetic studies such as gene complementation do not effectively allow for both induction and repression of gene expression. Additionally, there is no expression system available that can be induced in bacteria growing in vitro as well as in vivo, e.g. in eukaryotic cell lines or in living animal models. Here, we present a series of novel inducible low copy expression vectors that are well suited for use in the Yersinia species. Their tet operator/promoter/repressor system makes them distinct from other vectors, and gene transcription in bacteria can easily be induced by addition of anhydrotetracyline (ATc) either to the growth medium, to tissue culture medium during bacterial infections of cell lines or by injection into animals infected with bacteria. Researchers can choose between two different antibiotic resistances (kanamycin or spectinomycin), between two copy numbers (5 or 12-22) as well as between two different versions for expression from either the native RBS and ATG or RBS and ATG encoded in the plasmid. The whole vector series contains the same multi-cloning site from pBluescript II KS+ that allows for easy subcloning. Moreover, these vectors are built in a modular fashion that makes it simple to adapt them for other purposes. Finally, in addition to their use in Yersinia they are suitable for use in many other Enterobacteriaceae.

Indexed as

Genetic VectorsDrug Resistance, BacterialGene DosageGene Expression Regulation, BacterialMolecular Sequence DataPromoter Regions, GeneticReplication OriginRepressor ProteinsTetracyclinesYersiniaYersinia enterocolitica4-epianhydrotetracyclineRepressor Proteinstetracycline resistance-encoding transposon repressor proteinTetracyclines

Identifiers

PMID22445322
PMCPMC3367051
OpenAlexW2009307845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.